Triple drug cocktail shows promise against tough lung cancer

NCT ID NCT03377023

Ongoing Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a combination of three drugs—nivolumab, ipilimumab, and nintedanib—can safely shrink tumors in people with advanced non-small cell lung cancer that has no curative options. The trial involves 66 participants and is split into two phases: the first finds the safest dose, and the second measures how many patients respond. The goal is to see if this triple therapy can control the disease better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab, ipilimumab, and nintedanib
What this could lead to: If it works, this could offer a new treatment option for people with advanced non-small cell lung cancer who have few choices left.
What could go wrong: This is an early-phase trial with only 66 participants, so results may not apply to everyone. The three-drug combination may cause significant side effects, and it's not yet known if it works better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER, NONSMALL CELL NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER METASTATIC

Contacts and locations

Locations

H. Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.